^
Association details:
| Biomarker: | SAA2 overexpression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Transcriptomic changes underlying EGFR inhibitor resistance in human and mouse models of basal-like breast cancer
Published date:
12/08/2022
Excerpt:
Comparison of all three data types revealed five genes that were upregulated across all erlotinib-resistant samples: IL19, KLK7, LCN2, SAA1, and SAA2. Of these five genes, LCN2 was most abundantly expressed in triple-negative breast cancers, and its knockdown restored erlotinib sensitivity in vitro....These data could be used to identify a biomarker or develop a gene signature predictive of patient response to EGFRi.
DOI:
10.1038/s41598-022-25541-3
